^
    Back
    Association details:
    Biomarker:BCR-ABL1 fusion
    Cancer:Acute Lymphocytic Leukemia
    Drug:Hansoh Xinfu (flumatinib) (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASH 2022
    Title:

    4049 A Phase II Study of Flumatinib with Chemotherapy for Newly Diagnosed Ph/BCR-ABL1-Positive Acute Lymphoblastic Leukemia in Adults：Preliminary Results from RJ-ALL2020.2A Trial

    Published date:
    11/03/2022
    Excerpt:
    Pts who underwent HSCT had a relatively better outcome, with 1-year PFS rate significantly higher than non-HSCT group (95.7% vs. 52.2%, p=0.006) (Figure 1C), and 1-year OS rate tending to be higher (100% vs. 74.1%, p=0.145). Among 40 pts evaluable for ABL1 mutations, 14 pts were mutated...The combination of the second-generation TKI flumatinib and chemotherapy is quite effective and safe in Chinese adult pts with newly diagnosed Ph/BCR-ABL1+ ALL.
    Secondary therapy:
    Chemotherapy
    DOI:
    https://doi.org/10.1182/blood-2022-165259